Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovirdine SCHEMBL2231102 | 0.99 | ALDH1A1 (0.70) | ALDH1A1LTC4SKDM4ESMN1; SMN2HTT | |
| SCHEMBL6951326 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2HTTMAPT | |
| SCHEMBL29355043 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LTC4SKDM4ESMN1; SMN2MAPT | |
| SCHEMBL7624466 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LTC4SKDM4ESMN1; SMN2MAPT | |
| SCHEMBL30255323 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KDM4ESMN1; SMN2HTTMAPT | |
| SCHEMBL7224530 | 0.80 | LTC4S (0.87) | ALDH1A1LTC4SKDM4ESMN1; SMN2MAPT | |
| SCHEMBL6965655 | 0.80 | ALDH1A1 (0.71) | ALDH1A1LTC4SSMN1; SMN2HTTMAPT | |
| SCHEMBL7078039 | 0.80 | ALDH1A1 (0.72) | ALDH1A1KDM4ESMN1; SMN2MAPTNPSR1 | |
| SCHEMBL5390696 | 0.79 | ALDH1A1 (0.70) | ALDH1A1LTC4SKDM4ESMN1; SMN2MAPT | |
| SCHEMBL6902515 | 0.79 | ALDH1A1 (0.62) | ALDH1A1LTC4SSMN1; SMN2MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| EP-3664811-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-06-17 | — | — | EP | claimed |
| CN-105164143-B | Cholesterol vesicles for introducing molecules into chylomicrons | 杰罗米.J.申塔格 | 2019-02-19 | — | — | CN | claimed |
| WO-2019032749-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-02-14 | — | — | WO | claimed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | claimed |
| EP-2970369-A2 | CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS | Schentag, Jerome, J. (US) | 2016-01-20 | — | — | EP | claimed |
| CN-105164143-A | Cholesterol vesicles for introducing molecules into chylomicrons | SCHENTAG JEROME J | 2015-12-16 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | claimed |
| EP-0973753-A2 | 4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | claimed |
| WO-2000000475-A1 | SUBSTITUTED QUINOLIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | claimed |
| WO-2000000479-A1 | 1,3-BENZODIAZEPIN-2-ONES AND 1,3-BENZOXAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | claimed |
| WO-1999036406-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 1999-07-22 | — | — | WO | claimed |
| CN-1208405-A | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 1999-02-17 | — | — | CN | claimed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | claimed |
| EP-0876353-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | claimed |
| WO-1998045276-A2 | 4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-15 | — | — | WO | claimed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | claimed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | ALDH1A1 1200/4885LTC4S 522/4885KDM4E 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.